Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903548 · ClinicalTrials.gov registry record
Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 1
- Enrollment target
NCT04903548 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 1 participants.
The verdict
NCT04903548 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).
Interventions
- PROCEDURE SIRT with Y-90 resin microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2024-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903548
The ClinicalTrials.gov registry entry for NCT04903548 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SIRT with Y-90 resin microspheres is the first listed.
NCT04903548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04903548 about?
NCT04903548 is a clinical study titled "Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres". The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).
What is the current status of trial NCT04903548?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2021-01-08. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT04903548?
The interventions under investigation include: SIRT with Y-90 resin microspheres (PROCEDURE).
Who is sponsoring clinical trial NCT04903548?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.